ADAPY - Adaptimmune Therapeutics plc
NEXT EARNINGS:
Mar 10, 2026
(in 13 days)
EPS Est: $-0.06
|
Rev Est: $4.8M
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$2.83
DETAILS
HIGH:
$4.00
LOW:
$1.00
MEDIAN:
$3.00
CONSENSUS:
$2.83
UPSIDE:
14050.00%
Market Cap:
5.30M
Volume:
165,576
Avg Volume:
2,261,747
52 Week Range:
0.001-0.621
Sector:
Healthcare
Industry:
Biotechnology
Beta:
2.47
Last Dividend:
$N/A
Exchange:
OTC
Country:
GB
Employees:
506
IPO Date:
2015-05-06
EPS (TTM):
-0.05
P/E Ratio:
-1.92
Revenue (TTM):
178.03M
Total Assets:
245.96M
Total Debt:
74.21M
Cash & Equiv:
91.14M
Rev Growth (5Y):
175.4%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
-35.2%
Debt/Equity:
6.26
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2025-08-13 | $-0.11 | $-0.15 | +26.7% | $13.7M | $12.9M | +5.8% |
| 2025-05-13 | $-0.18 | $-0.18 | 0.0% | $7.3M | $8.7M | -15.9% |
| 2025-03-24 | $-0.26 | $-0.17 | -52.9% | $3.2M | $8.4M | -61.7% |
| 2024-11-13 | $-0.07 | $-0.17 | +58.8% | $40.9M | $11.2M | +266.2% |
| 2024-08-12 | $0.24 | $-0.07 | +442.9% | $128.2M | $11.2M | +1048.0% |
| 2024-05-15 | $-0.18 | $-0.10 | -80.0% | $5.7M | $10.7M | -47.1% |
| 2024-03-06 | $-0.24 | $-0.10 | -140.0% | $233009 | $5.6M | -95.9% |
| 2023-11-08 | $-0.20 | $-0.12 | -66.7% | $7.3M | $20.5M | -64.2% |
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 178.03M | 60.28M | 27.15M | 6.15M | 3.96M | 1.12M | 59.51M | 37.83M | 14.20M | 10.72M | 604,625 | 0 |
| Net Income | (70.81M) | (113.87M) | (165.46M) | (158.09M) | (130.09M) | (137.16M) | (95.51M) | (70.14M) | (71.58M) | (21.59M) | (12.70M) | (8.46M) |
| EPS | -0.05 | -0.09 | -0.17 | -0.17 | -0.15 | -0.22 | -0.16 | -0.13 | -0.17 | -0.10 | -0.04 | -0.08 |
| Total Assets | 245.96M | 282.62M | 328.92M | 469.55M | 451.14M | 181.54M | 276.74M | 281.15M | 234.51M | 300.68M | 55.52M | 1.81M |
| Total Debt | 74.21M | 25.23M | 23.08M | 25.47M | 23.71M | 25.46M | 136.75M | 124.22M | 0 | 0 | 0 | 1.54M |
| Cash & Equivalents | 91.14M | 143.99M | 108.03M | 149.95M | 56.88M | 50.41M | 68.38M | 84.04M | 158.78M | 229.06M | 51.27M | 247,791 |
| Operating Cash Flow | (73.21M) | (140.88M) | (141.77M) | 10.73M | (53.59M) | (112.51M) | (104.39M) | (54.31M) | (48.17M) | (32.74M) | 37.23M | (7.77M) |
| Free Cash Flow | (75.93M) | (145.76M) | (171.51M) | 1.95M | (56.50M) | (115.58M) | (109.10M) | (79.33M) | (60.95M) | (37.85M) | 35.78M | (7.92M) |
| FCF per Share | -0.05 | -0.12 | -0.18 | 0.00 | -0.07 | -0.18 | -0.19 | -0.15 | -0.14 | -0.18 | 0.12 | -0.08 |
| Book Value | 11.85M | 39.51M | 81.88M | 205.96M | 341.23M | 123.64M | 246.88M | 202.98M | 166.14M | 259.61M | 2.41M | (2.16M) |
| Cash & ST Investments | 151.60M | 146.94M | 204.60M | 369.58M | 368.22M | 89.54M | 205.13M | 208.26M | 181.47M | 284.36M | 51.27M | 247,791 |
| ROC Equity | -5.98 | -2.88 | -2.02 | -0.77 | -0.38 | -1.11 | -0.39 | -0.35 | -0.43 | -0.08 | -5.27 | N/A |